An Open-Label, Multicenter, Randomized Controlled Phase III Clinical Study of Neoadjuvant Chemotherapy Based on SNF Classification With or Without Precision Medicine Agents for Early-Stage or Locally Advanced HR+/HER2- Breast Cancer
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Adebrelimab (Primary) ; Famitinib (Primary) ; Fuzuloparib (Primary) ; Rivoceranib (Primary)
- Indications HER2 positive breast cancer
- Focus Therapeutic Use
- 11 Apr 2025 New trial record